Topics
Glioblastoma | Treatment | Targeted therapy | BMS-986205
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > BMS-986205
Lukas RV, Zhai L, Lauing KL, Kim M, Koch T, Penco-Campillo M,
Bommi P, Dixit K, Kumthekar P, Sharp L, Lezon R, Garcia D,
Sonabend AM, McCortney K, Castro BA, Chandler JP, Gondi V, Grimm
SA, Miska JM, Heimberger AB, Dobinda K, Zhang H, Sachdev S, Juhasz
C, James CD, Allen JM, Horbinski C, Lesniak MS, Stupp R,
Wainwright DA.
Phase 1 evaluation of
patients with newly diagnosed glioblastoma treated with radiation,
nivolumab, and IDO1 enzyme inhibitor BMS-986205.
Clin
Cancer Res. 2026 May 26. doi:
10.1158/1078-0432.CCR-26-1124. PMID:
42189896. Trial
registration ID: NCT04047706.
ˍ